Eurand, a global specialty pharmaceutical company, announced today the grant of US Patent No. 7,658,918, titled ‘Stable digestive enzyme compositions’, by the United States Patent and Trademark Office (USPTO). The patent will provide Eurand with coverage until at least 20 February 2028 on ZENPEP® (pancrelipase) delayed-release capsules.

In 2009, the US Food and Drug Administration (FDA) granted ZENPEP five years of marketing exclusivity as a new chemical entity.